Annals of Oncology Advance Access originally published online on September 15, 2006
Annals of Oncology 2006 17(11):1709-1717; doi:10.1093/annonc/mdl282
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
phase I and pharmacokinetics |
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
1 Department of Pediatrics, Medical Oncology, and Pharmacology, University of Colorado Cancer Center, Aurora, CO, USA
2 Department of Medical Oncology, University of Virginia, Charlottesville, VA, USA
3 Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
4 Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium
*Correspondence to: Dr L. Gore, University of Colorado Health Sciences Center at Fitzsimons, Pediatrics, Mail Stop 8302, PO Box 6511, Aurora, CO 80045, USA. Tel: 303-724-4011; Fax: 303-724-4015; E-mail: lia.gore{at}UCHSC.edu
Background: To evaluate the toxicity and pharmacological and biological properties of the farnesyl protein transferase (FPTase) inhibitor, tipifarnib (R115777, ZARNESTRATM) and capecitabine administered for 14 days every 3 weeks.
Patients and methods: Patients with advanced cancers received twice daily tipifarnib (100–500 mg) and capecitabine (1000–1125 mg/m2) for 14 days every 3 weeks. Pharmacokinetics of tipifarnib, capecitabine and 5-fluorouracil (5-FU) were determined. Peripheral blood mononuclear cells were analyzed for farnesylation of the HDJ2 chaperone protein and FPTase activity.
Results: Forty-one patients received 185 courses of treatment. Diarrhea and palmar–plantar erythrodysesthesia were dose limiting at 300 mg tipifarnib/1125 mg/m2 capecitabine b.i.d. When the capecitabine dose was fixed at 1000 mg/m2 b.i.d., neutropenia was dose limiting at 400 and 500 mg b.i.d. of tipifarnib. Capecitabine did not affect the pharmacology of tipifarnib at 100–300 mg b.i.d., although tipifarnib significantly increased the Cmax of 5-FU at 400 mg b.i.d. HDJ2 farnesylation and FPTase activity decreased between 200 and 400 mg b.i.d. doses of tipifarnib, without a dose–response relationship. Five patients demonstrated partial remissions and 11 patients maintained prolonged stable disease.
Conclusions: Tipifarnib and capecitabine are well tolerated at 300 mg/1000 mg/m2 b.i.d., respectively, resulting in biologically relevant plasma concentrations and antitumor activity. The recommended dose for further disease-focused studies is 300 mg b.i.d. tipifarnib and 1000 mg/m2 b.i.d. capecitabine, given for 14 days every 3 weeks.
Key words: capecitabine, farnesyltransferase inhibitor, pharmacokinetics, phase I, tipifarnib
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Findlay, G. von Minckwitz, and A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann. Onc., February 1, 2008; 19(2): 212 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-A. Martin, J. E. Head, S. Pancholi, J. Salter, E. Quinn, S. Detre, S. Kaye, A. Howes, M. Dowsett, and S. R.D. Johnston The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo Mol. Cancer Ther., September 1, 2007; 6(9): 2458 - 2467. [Abstract] [Full Text] [PDF]
|
|